| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb5c3e043be2938225be32a9ff286d8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d6ca7c8e8b196572e30e4aa44a78cd0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
| filingDate |
1994-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd97a2db49c8565c6802eef475723da0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56ca3d27c081952c2865e2e65b62e5a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d077409630157e9981e06aefab625701
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7736c502ea5f0bc9d55ad974062d3bc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcc280aee74353721aead35a431da835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_985e73c0f544938e0bb868af63a86960
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54a29263e064b0b0c8755aedca565c7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b00d4ef86da30b2423c2703287d5a05 |
| publicationDate |
1995-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9507929-A1 |
| titleOfInvention |
Multiple branch peptide constructions for use against hiv |
| abstract |
Multiple branch peptide constructions formed from peptides derived from the V3 loop of gp120 protein of HIV-1, and including the consensus sequence GPGR preceded by 0 to 4 amino acids and succeeded by 2 to 4 amino acids, preferably not including I in the 3 amino acids immediately preceding GPGR and most preferably GPGRAF, show increased receptor affinity and prevent cell-to-cell fusion. They have a direct virostatic effect. Because they present the same peptide sequence several times, these MBPCs are able to neutralize in vitro the different steps of virus envelope/cell membrane fusion, and infected cell membrane/uninfected cell membrane fusion of several strains of HIV-1 and HIV-2. Notably, they are effective in blockading both CD4 receptors on lymphocytes and macrophages and GalCer receptors on colon epithelial cells. These results open a potential use in treatment of HIV-1 and HIV-2 infection. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9529190-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009032605-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009032605-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9934777-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6610304-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9829443-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004104031-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2004240765-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004104031-A3 |
| priorityDate |
1993-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |